New HIV prevention pill shows promise in Real-World study

NCT ID NCT04233372

Completed Prevention Sponsor: Hospital Clinic of Barcelona Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether a three-drug HIV pill called Delstrigo can prevent HIV infection when taken for 28 days after a possible exposure. About 400 adults who came to the emergency room after a potential HIV contact took the pill daily. Researchers tracked how many completed the full course and what side effects occurred.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Delstrigo (doravirine, lamivudine, tenofovir disoproxil fumarate)
What this could lead to: If successful, this could provide a simpler, well-tolerated option for preventing HIV after a potential exposure.
What could go wrong: This is a single-site, open-label study without a comparison group, so results may not apply broadly. Some people may not complete the full 28-day course.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Department and HIV & HCV Clinical Research Unit University Hospital Nantes

Nantes, France
Hospital Clínic de Barcelona

Barcelona, 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.